Peer-Reviewed Journal Details
Mandatory Fields
McGuire, A,Casey, MC,Shalaby, A,Kalinina, O,Curran, C,Webber, M,Callagy, G,Holian, E,Bourke, E,Kerin, MJ,Brown, JAL
2019
March
Scientific Reports
Quantifying Tip60 (Kat5) stratifies breast cancer
Published
Optional Fields
HISTONE ACETYLTRANSFERASE LYSINE ACETYLTRANSFERASES INHIBITORS ARGONAUTE2 EXPRESSION CHROMATIN DROSHA DICER AGO2
9
Breast cancer is stratified into four distinct clinical subtypes, using three key biomarkers (Her2/Neu gene status, Estrogen and Progesterone receptor status). However, each subtype is a heterogeneous group, displaying significant variation in survival rates and treatment response. New biomarkers are required to provide more precise stratification of breast cancer cohorts to inform personalised treatment options/predict outcomes. Tip60 is a member of the MYST sub-family of histone acetyltransferases (HATs), and is directly involved in genome maintenance, gene regulation and DNA damage response/repair pathways (key chemotherapeutic influencing mechanisms). We aimed to determine if quantifying Tip60 staining patterns improved breast cancer stratification. We defined Tip60 protein in vivo, quantifying location (cytoplasmic, nuclear), percent of cells and staining intensity in a breast cancer tissue microarray (n = 337). A significant association of specific Tip60 staining patterns with breast cancer subtype, ER or PR status and Tumour grade was found. Importantly, low Tip60 mRNA expression correlated with poor overall survival and relapse free survival. We found Tip60 is a biomarker able to stratify breast cancer patients, and low Tip60 expression is a significant risk factor indicating a higher chance of disease reoccurrence. This work highlights Tip60 regulation as a key factor influencing the development of breast cancer.
10.1038/s41598-019-40221-5
Grant Details
Publication Themes